• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Crinetics Pharmaceuticals, Inc. - Common Stock (NQ: CRNX )

    53.60 +0.86 (+1.63%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,940,469
    Open 52.28
    Bid (Size) 21.33 (2)
    Ask (Size) 54.05 (1)
    Prev. Close 52.74
    Today's Range 51.73 - 54.25
    52wk Range 33.67 - 62.53
    Shares Outstanding 54,026,103
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
    Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation. 
    Via Benzinga
    Exposures Product Safety
    Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +51.46%
    +51.46%
    1 Month
    -6.01%
    -6.01%
    3 Month
    +6.31%
    +6.31%
    6 Month
    +17.39%
    +17.39%
    1 Year
    +49.26%
    +49.26%

    More News

    Read More
    Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 12, 2024
    Via Benzinga
    What Analysts Are Saying About Crinetics Pharmaceuticals Stock
    Via Benzinga
    A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
    Via Benzinga
    Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.